Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Early and aggressive initiation of insulin therapy for type 2 diabetes: what is the evidence?
Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Early and aggressive initiation of insulin therapy for type 2 diabetes: what is the evidence?Tags: Scdl Solved AssignmentsPoverty Research PapersWww.Creative Writing.ComBusiness Planning QuestionsTerm Paper ReferenceEssay Writing For High School StudentsEssay On Current Political Issues
Monnier L, Benichou M, Charra-Ebrard S, Boegner C, Colette C.
Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of Hb A(1c).
Case 1 Topics • Background• Current Visit• Laboratory Results• Clinical Discussion• Endocrinologist Consultation• New Treatment Regimen With Add-On Therapy• Conclusions Case 2 Topics • Background• Current Visit: Exam Findings• Current Treatment Regimen• Health History• Laboratory Results• Clinical Discussion• Cardiologist Visit• Three Months After Visiting the Cardiologist• Add-On Therapy With Welchol for Patients With T2DM and CHD• Treatment Goals for Alice• Conclusions Faculty/Faculty Disclosures Yehuda Handelsman, MD, FACP, FACEMedical Director Metabolic Institute of America Chair and Program Director7th World Congress on Insulin Resistance Chair, International Committeefor Insulin Resistance18372 Clark Street, Suite 212Tarzana, CA 91356E-mail:[email protected] Site:
The Metabolic Dr Handelsman is a consultant for Bristol-Myers Squibb Company, Daiichi Sankyo, Inc., Glaxo Smith Kline, Medtronic, Merck, Tethys,and Xoma; he has received clinical research grant funding from Daiichi Sankyo, Inc., Glaxo Smith Kline, Novo Nordisk, and Takeda; and he ison the speakers bureau for Astra Zeneca, Bristol-Myers Squibb, Daiichi Sankyo, Inc., Glaxo Smith Kline, Merck, and Novartis.
Alterations of carbohydrate and lipoprotein metabolism in childhood obesity--impact of insulin resistance and acanthosis nigricans.
Felszeghy E, Kaposzta R, Juhasz E, Kardos L, Ilyes I.
Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study).
Relationship of fasting and hourly blood glucose levels to Hb A1c values: safety, accuracy, and improvements in glucose profiles obtained using a 7-day continuous glucose sensor. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Sustained benefit of continuous glucose monitoring on A1C, glucose profiles, and hypoglycemia in adults with type 1 diabetes.
Haak T, Tiengo A, Draeger E, Suntum M, Waldhausl W. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group, Bode B, Beck RW, et al.
Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: experience from the PRESENT study.